PBAC rejects semaglutide listing for severe obesity
It was Novo Nordisk's second application for taxpayer funding.
Semaglutide manufacturer Novo Nordisk has lost its second bid for Wegovy to be PBS-listed as a severe obesity treatment, with the PBAC deciding it would not be cost-effective for taxpayers.
Wegovy — which has the same active ingredient as Ozempic — is TGA-registered for treating obesity or overweight in patients with one or more weight-related comorbidities.
